“Alpelisib (BYL719) induced a disease control rate (DCR) of 58.2% in patients with advanced solid tumors, according to results from a phase Ia study published in the Journal of Clinical Oncology.
“Treatment with the oral PIK3CA selective inhibitor led to a stable disease rate of 52.2%. Thirteen (9.7%) patients maintained stable disease for more than 24 weeks.
“Investigators reported ‘encouraging signs of antitumor activity’ in patients with PIK3CA-mutant, ER-positive/HER2-negative breast cancer, and other PIK3CA-altered advanced solid tumors.”
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.